Illumina Expands Portfolio of Standard SNP Genotyping Products and Services Company Launches New Products for Genetic Linkage Analysis and Fine Chromosomal Mapping
Businesswire, Wednesday, January 08, 2003 at 12:17
SAN DIEGO, Jan 8, 2003 (BUSINESS WIRE) -- Illumina, Inc. (Nasdaq: ILMN) announced today the availability of two new SNP genotyping product offerings developed for the Company's BeadArray(TM) technology platform. The standard products -- one for genetic linkage analysis and the other for fine chromosomal or whole-genome mapping -- are being deployed in Illumina's genotyping services operation and will also be available for customers who use Illumina's production-scale genotyping solution.
According to Jay Flatley, Illumina President and CEO,"We're excited about expanding our standard product portfolio, as these high-value offerings address a rapidly growing market opportunity. Equally important, these new offerings demonstrate the robustness of Illumina's development processes and manufacturing capability."Flatley added,"We've worked closely with GlaxoSmithKline and other collaborators on SNP selection, assay development and new product design."Family linkage analysis can help identify chromosomal regions with potential disease associations. Illumina's new linkage panel is a second-generation product based on over 3500 SNP locations with high minor-allele frequency, even distribution across the human genome and coverage across both sex chromosomes. Studies with large sample populations typically require less than 45 days to complete, while delivering extremely high genotyping accuracy.
Complementing the linkage product is a new, SNP-based fine mapping product that provides dense genotyping (greater than 1000 markers on average per chromosome) and may enable target gene identification based on SNP loci implicated in a specific disease. The fine mapping product is derived from a large genotyping study recently completed for GlaxoSmithKline (GSK). In the course of the study, GSK and Illumina collaborated to develop an extensive set of SNP markers into validated SNP assays. The fine mapping product may be used to genotype selected chromosomal regions or assayed against the whole human genome.
Like the linkage analysis product, the fine mapping assays are designed for high multiplexing and optimized for Illumina's Sentrix(TM) 96 array matrix, which can process in parallel nearly 150,000 individual assays. Assay protocols for the new genotyping products require low reagent volumes and perform at the lowest running cost in the industry.
Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine |
